Legend Biotech stock has fallen sharply over the past few years, yet the broader valuation checks still lean cheap based on current market multiples. That gap between a weak share price record and a relatively positive valuation screen is what many investors are trying to make sense of now.

Over the past 3 years the share price declined about 69.8%, which leaves existing holders facing heavy losses and raises the question of whether current levels already reflect much of the bad news.
Future revenue growth from Legend Biotech’s cell therapy portfolio can support the current share price. However, execution risk around clinical progress and funding needs may limit how much value the market is willing to assign today.
The company screens undervalued on most checks, with a high value score of 5, which suggests the broader snapshot leans cheap rather than expensive.

The issue now is whether Legend Biotech’s weak long term share performance already captures the key risks or if the stock still does not offer enough compensation for them at the current price.

Broaden your hunt for undervalued opportunities by comparing Legend Biotech with hand-picked companies in the 45 high quality undervalued stocks.

Does Legend Biotech Look Undervalued on Sales?

The P/S ratio is a useful cross check for Legend Biotech because the company is still working through losses and sales provide a cleaner anchor than earnings. Legend Biotech currently trades on a P/S of about 3.2x, which is below the broader biotech industry average of 13.1x and also below the peer average of 9.2x.

The model based fair P/S ratio for Legend Biotech is 5.7x, which factors in its sector, scale and risk profile. The current 3.2x level sits at a discount to that fair ratio, so the market is valuing each dollar of Legend Biotech revenue more conservatively than both the industry benchmarks and the tailored model indicate.

On this P/S multiple, Legend Biotech stock appears undervalued compared with both its peers and the model based fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Legend Biotech Narrative: What Would Justify Today’s Price?

Simply Wall St Narratives for Legend Biotech aim to close the gap between the stock’s weak share performance and its apparently low valuation by spelling out which assumptions on future growth, margins and earnings would need to hold for the company to be worth meaningfully more or less than today. Rather than relying on a single multiple or model output, each Narrative sets out the assumptions behind its fair value so you can compare them with Legend Biotech’s actual results over time.